Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study
Journal of Alzheimer’s Disease · 21.11.2026
DOI: 10.1177/13872877261507035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 21.11.2026. Verfasst von Pamela L. Lutsey und 8 weiteren Autor:innen. Die Arbeit nennt 61 Literaturangaben. Gefördert von: American Heart Association, National Institute of Neurological Disorders and Stroke, National Institute on Aging.
Themen: Demenz, Schlaganfall
Abstract (Originalsprache)
Background
Elevated concentrations of fibroblast growth factor 23 (FGF23), a hormone involved in bone mineral and vitamin D metabolism, may be associated with risk of stroke and dementia through inflammation, endothelial dysfunction, vessel calcification and stiffness, and axonal degeneration.
Objective
We tested the hypothesis that elevated FGF23 is associated with increased risk of dementia and stroke.
Methods
FGF23 was measured in serum samples collected in 1990–1992 from 12,391 participants of the Atherosclerosis Risk in Communities study. Participants were followed through 2019 for incident stroke and dementia. Cox regression was used to examine the associations of FGF23 (in quintiles) with risk of stroke and dementia, with adjustment for demographics, cardiovascular and dementia risk factors, and kidney function.
Results
Participants (mean 56.9 years; 57% female) were followed a median of 24 years; 1183 developed stroke and 2402 developed dementia. Participants in the highest versus lowest quintile of serum FGF23 were at elevated risk of stroke [HR (95% CI): 1.27 (1.06–1.51)] and dementia [HR: 1.21 (1.06–1.38)] independent of baseline demographics. Associations attenuated with additional adjustment for traditional cardiovascular risk factors [HR stroke : 1.20 (1.00–1.45); HR dementia : 1.17 (1.03–1.35)], and became even weaker after accounting for eGFR [HR stroke : 1.13 (0.94–1.37); HR dementia : 1.14 (1.00–1.31)]. The associations of FGF23 with incident stroke and dementia were not modified by categories of age, sex, race, or eGFR.
Conclusions
Higher FGF23 was associated with modestly greater risk of stroke and dementia in this population-based sample, though the association was largely attenuated after adjustment for traditional cardiovascular risk factors and kidney function.
Förderung
- American Heart Association
- National Institute of Neurological Disorders and Stroke
- National Institute on Aging
- National Heart, Lung, and Blood Institute
Zitieren
APA
Lutsey, P. L., Sauerer, D. M., Michos, E. D., Selvin, E., Rebholz, C. M., Gottesman, R. F., Alonso, A., Matsushita, K., & Sedaghat, S. (2026). Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877261507035
Vancouver
Lutsey PL, Sauerer DM, Michos ED, Selvin E, Rebholz CM, Gottesman RF, et al. Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877261507035
BibTeX
@article{Lutsey2026,
author = {Lutsey, Pamela L. and Sauerer, Devon M. and Michos, Erin D. and Selvin, Elizabeth and Rebholz, Casey M. and Gottesman, Rebecca F. and Alonso, Alvaro and Matsushita, Kunihiro and Sedaghat, Sanaz},
title = {Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
doi = {10.1177/13872877261507035}
}
EUVIMED